Cardax, Inc. Stock Price - CDXI

0.00 (0.0%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardax, Inc. (QB) CDXI OTC BB Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 6.00 0.00 0.00 0.00 6.00 17:00:05
Stock Trades Traded Volume Average Volume 52 Week Range
1 2 1,261 0.032 - 6.45
Last Trade Time Type Quantity Stock Price Currency
15:36:09 2 $ 6.15 USD

Cardax, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 4.55M 758.97k $ -4.26M - - 277.87k
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cardax, Inc. News

Loading Messages....

Latest CDXI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CDXI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.
1 Month5.756.255.756.053730.254.35%
3 Months0.056.450.045050.56720513,9705.9511,900.0%
6 Months0.076.450.0320.080474240,8355.938,471.43%
1 Year0.186.450.0320.102317136,8445.823,233.33%
3 Years0.216.450.0320.205173646,4435.792,757.14%
5 Years0.256.450.030.181828644,9715.752,300.0%

Cardax, Inc. Description

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health. CDX-101, the Company's astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company's zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. The Company's pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. The safety and efficacy of the Company's pharmaceutical candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

Your Recent History
Cardax, In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.